Business Wire

BCDIPLOMA

Share
BCdiploma and ETS Global join forces to digitise TOEIC® score reports for use in Europe

How can organisations protect against fraudulent certifications or fake English assessment test results? How can test takers in Europe receive their TOEIC ® test results in one click? How can test takers in Europe be sure that their test results are certified, tamper-proof and secure? To answer these questions, ETS Global, a subsidiary of ETS, chose to collaborate with BCdiploma, the industry-leading company for the digitisation of academic documents via blockchain technology. In Europe, ETS Global and BCdiploma are working on securing hundreds of thousands of digital TOEIC score reports via blockchain. For ETS Global, this is another step in its digital transformation. Starting from January 2022, TOEIC digital score reports are available in France and will be available across Europe during 2022.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220223005682/en/

The result of this collaboration between these two leading players is a digital TOEIC score report that is :

  • Secure: the storage of data on the blockchain makes it impossible to falsify the score report. BCdiploma complies with the strictest data protection regulations. In addition to the blockchain's encryption, BCdiploma adds its own secure, patented algorithms. This way, ETS Global and test takers retain full control over their data, which search engines cannot find or list.
  • Universal: BCdiploma adapts to all consultation or sharing standards such as Verifiable Credentials from W3C and EBSI, Open Badges, EDCI, and more.
  • User-friendly: available online in one click, this digitised document can be downloaded and sent by email, printed or exported in PDF format. A QR code is added to the document, which the test taker or the recipient of the certification can scan.
  • Faster : because results are sent by email, test taker receive their scores faster compared to paper score report shipped by post.
  • Streamlined: this digitalisation saves time for universities, schools and training organisations. The sending of results to test takers is automated. As for recruiters, they have access to a certified certificate, avoiding the need for inefficient "fact checking" to verify the authenticity of the document.
  • More innovative : for the test taker, sending a secure link or a QR code of a certification guarantees quality and presents a modern picture to recruiters.
  • More "carbon compatible"*: TOEIC digital score reports are issued using "Avalanche®", the latest generation and one of the most energy-efficient blockchains. Besides, stopping printing score reports will enable ETS Global to save seven trees/year. And without any paper score report to ship to test takers, ETS Global's carbon footprint will decrease by about 490kg of CO2 /year.

Miguel Membrado, Chief Digital Officer of ETS Global says: "The digitalisation of the education sector has been accelerating for years, and even more so since the start of the pandemic. Being able to offer digital TOEIC® test score reports to all ETS Global stakeholders is an obvious choice. We are delighted to be working with BCdiploma, a leading player in this field. As of today, we are offering this service to our test takers in Europe at no additional cost with the goal that within six months, the use of paper score reports in Europe will decline in favour of digital. This is not a war between digital and paper. Our customers will have the choice, of course. But we are convinced of the benefits of digitalisation to the overall customer experience, which this project perfectly illustrates."

Luc Jarry-Lacombe, CEO of BCdiploma, adds: "Our job as a software publisher is to reinvent a diploma that fits into the Digital Workplace. Better yet, it's about bringing the benefits of the blockchain system to test takers, recruiters, and all training organisations and institutions. 50% to 60% of our costs are dedicated to R&D, which enables us to deliver an impeccable service with the latest blockchain technologies. We are very happy to collaborate with the ETS Global teams, to offer more than a diploma: a real quality marketing object."

*already available in France. Deployment in Europe in  2022

About BCdiploma
BCdiploma has been trusted by more than 120 institutions, universities, and businesses in 18 countries. Our patented technology takes advantage of the latest blockchain and distributed storage technologies to deliver a high value Digital Credentials service. Our team brings to institutions a recognised expertise to succeed in their digital transformation projects. https://www.bcdiploma.com/en

About ETS Global
ETS Global B.V., a wholly owned subsidiary of ETS, is the international arm of ETS.  At ETS Global B.V., we bring expertise to educational and business communities around the world, including companies, language schools, academic institutions and public service organisations. ETS Global serves 80 countries and offers a range of ETS products, services and learning solutions. https://www.etsglobal.org/fr/en

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release

Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi

Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse

Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye